Investor Presentation H1 2023

28 Investor presentation First six months of 2023 Novo NordiskⓇ Novo Nordisk holds solid patent protection, competitive advantages and a collaborative approach to Novo Nordisk's position is protected by patents and value chain setup OZEMPİC semaglutide injection RYBELSUS® semaglutide tablets Fiasp fast-acting insulin aspart esperoct turoctocog alfa pegol Xultophy insulin degludec/liraglutide [rDNA origin] injection EU/US patent protection1 2031/322 2031/20322,3 20304 2034/322 2028/29 • TRESIBA 2028/29 insulin degludec [rDNA origin] injection RYZODEG 2028/29 70% insulindegudec and 30% insulin aspart [rDNA origin injection refixia® VICTOZAⓇ liraglutide injection 2027/28 20235 • Novo Nordisk holds competitive advantages compared to biosimilars Research & Development Need to show comparability in PK/PD trials Strict regulatory requirements in the EU and the US Requirement for both drug and device offering Manufacturing Economies of scale Up-front CAPEX requirements with slow return on investment Commercialisation Large and fragmented target audience Cost pressure from payers On-going conversion to next-generation drugs and slow market dynamics innovation Partnerships and acquisitions support future R&D siRNA treatments Dicerna TM Oral formulations of therapeutics Combination treatments for NASH GILEAD Gene editing for haemophilia Emisphere seventybio? Novel treatments for CVD/Rare disease CORVIDIA Precision Cardiovascular Therapeutics prothena Heartseed forma THERAPEUTICS. Novel treatments for metabolic diseases inversago X PHARMA 1 List does not include all marketed products. 2 Current estimates. WegovyⓇ patent identical to OzempicⓇ patent; 3 Tablet formulation and once-daily treatment regimen are protected by additional patents expiring in 2031-2034; 4 Formulation patent; active ingredient patent has expired; PK: Pharmacokinetic, PD: Pharmacodynamic; CAPEX: Capital expenditure; siRNA: Silencing ribonucleic acid; NASH: Non-alcoholic steatohepatitis; CVD: Cardiovascular disease

View entire presentation